Key Financial Figures - Standalone (H1 FY27)
Income Statement Highlights:
- Revenue from operations: ₹5,956.91 lakhs (vs ₹4,625.86 lakhs in H1 FY26)
- Total income: ₹6,102.69 lakhs (vs ₹4,790.17 lakhs in H1 FY26)
- Profit before tax: ₹1,534.58 lakhs (vs ₹1,110.46 lakhs in H1 FY26)
- Net profit: ₹1,159.58 lakhs (vs ₹841.71 lakhs in H1 FY26)
- Basic and diluted EPS: ₹9.70 (vs ₹7.26 in H1 FY26)
Balance Sheet Position (as of September 30, 2026):
- Total equity and liabilities: ₹17,456.89 lakhs (vs ₹15,919.06 lakhs as of March 31, 2026)
- Share capital: ₹1,195.70 lakhs
- Reserves and surplus: ₹9,563.55 lakhs
- Total assets: ₹17,456.89 lakhs
Quarterly Performance (Q2 FY27):
- Revenue from operations: ₹3,272.68 lakhs
- Net profit: ₹657.83 lakhs
- EPS: ₹5.50
Key Financial Figures - Consolidated (H1 FY27)
Income Statement Highlights:
- Revenue from operations: ₹8,080.23 lakhs (vs ₹4,962.17 lakhs in H1 FY26)
- Total income: ₹8,234.36 lakhs (vs ₹5,332.41 lakhs in H1 FY26)
- Profit before tax: ₹1,541.22 lakhs (vs ₹731.26 lakhs in H1 FY26)
- Net profit after minority interest: ₹1,162.72 lakhs (vs ₹726.20 lakhs in H1 FY26)
- Basic and diluted EPS: ₹9.72 (vs ₹6.32 in H1 FY26)
Balance Sheet Position (as of September 30, 2026):
- Total equity and liabilities: ₹25,317.57 lakhs (vs ₹23,682.90 lakhs as of March 31, 2026)
- Share capital: ₹1,195.70 lakhs
- Reserves and surplus: ₹9,827.71 lakhs
- Minority interest: ₹849.80 lakhs
- Total assets: ₹25,317.57 lakhs
Quarterly Performance (Q2 FY27):
- Revenue from operations: ₹4,708.40 lakhs
- Net profit after minority interest: ₹659.68 lakhs
- EPS: ₹5.69
Subsidiary Information
The consolidated results include the following subsidiaries:
- TNS Pharma Private Limited (51% ownership)
- TLL Parenterals Limited (51% ownership)
- Trident Mediquip Limited (59.67% ownership, increased from 58.67%)
- TLL Elements Private Limited (100% ownership)
- TLL Wellness Limited (formerly TLL Herbal Limited) (51% ownership)
Management Approvals
- Results reviewed by Audit Committee and approved by Board of Directors on October 26, 2026
- Signed by Chairman & Executive Director Hardik Desai (DIN: 01358227), CFO Director Ashish Bafna (DIN: 01796556), and Managing Director Shravan Patel (DIN: 08629141)
Additional Notes
- No investor complaints pending during the period
- Figures for previous periods have been re-grouped/re-stated for comparability
- Management assessment indicates no significant impact on carrying amounts of inventories, trade receivables, investments and other financial assets